Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)

Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?: Not FDA-cleared for chronic prostatitis / chronic pelvic pain syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and only as an adjunct within UPOINT-directed multimodal therapy.
Welche Evidenz existiert?: Tier C (investigational). Only small uncontrolled case series describe NIH-CPSI score reduction after extended-protocol hirudotherapy. There are no controlled trials. NIH Category III chronic prostatitis/CPPS accounts for the great majority of prostatitis presentations and is best managed by UPOINT-directed multimodal therapy: Urinary symptoms (alpha-blockers), Psychosocial (CBT, mental health), Organ-specific (anti-inflammatories, urology evaluation), Infection (antibiotic trial only if culture-positive), Neurologic (gabapentinoids, tricyclics), and Tenderness (pelvic-floor physical therapy). Heterogeneous CPPS phenotypes, strong placebo effects, and confounding by concurrent multimodal therapy limit interpretation of any uncontrolled findings.
Hauptrisiken: Bleeding from bite sites for 6 to 24 hours after detachment
Bruising and tenderness in the sacral or perineal region for 5 to 14 days
Local skin infection or Aeromonas infection (region is anatomically near anus and genitals)
Allergic reaction to leech saliva
Worsening of pelvic-floor spasm if bite is placed too close to a trigger area
Delay of UPOINT-directed multimodal therapy components
Risk of complications if perineal placement is attempted without an experienced operator
Missed Category I or II (bacterial) prostatitis if culture-guided antibiotics have not been considered
Wer dies nicht in Betracht ziehen sollte: Patients with NIH Category I (acute) or Category II (chronic bacterial) prostatitis (antibiotics first)
Patients with active urinary tract infection
Patients within 6 weeks of prostate biopsy
Patients on anticoagulation for a cardiac indication
Patients with perineal skin breakdown
Patients who have not engaged with pelvic-floor physical therapy and standard pharmacotherapy
Was Sie Ihren Kliniker fragen sollten: Has bacterial prostatitis been ruled out by culture (NIH Category I or II)?
Have I been UPOINT-phenotyped, and which domains are positive in my case?
Am I receiving multimodal therapy: alpha-blocker, pelvic-floor PT, neuropathic agents if indicated, CBT?
Where exactly will the leech be placed — sacral reflex zones, or perineal?
What is the practitioner's experience with this indication and Aeromonas-prevention plan?
What is the realistic expected benefit, given evidence is uncontrolled case series only?
Wann dringende medizinische Versorgung suchen: Fever above 38.0 C / 100.4 F, chills, or rigors (rule out bacterial prostatitis or urosepsis)
Inability to urinate or severe urinary urgency with retention
Visible blood in urine or perineal hematoma
Severe testicular, perineal, or lower abdominal pain (rule out epididymitis or other acute pathology)
Bleeding from a bite site lasting more than 24 hours
Spreading redness, warmth, pus, or red streaks at any bite site

Was dies NICHT bedeutet

It does not replace UPOINT-directed multimodal therapy, which has the strongest evidence base.
It does not treat bacterial prostatitis (Category I or II), which requires antibiotics.
It does not substitute for pelvic-floor physical therapy, which is one of the highest-yield components of CPPS care.
Only uncontrolled case series exist; benefit is uncertain.

Sicherheits-Querverweise

Clinical Profile

Category: urogenital
ICD-10: N41.1, N41.4, N41.9
Safety tier: high

Evidence Summary

Chronic prostatitis/CPPS (NIH Category III) accounts for roughly 90% of prostatitis presentations and is best managed by UPOINT-directed multimodal therapy (Urinary, Psychosocial, Organ-specific, Infection, Neurologic, Tenderness), with pharmacotherapy (alpha-blockers, NSAIDs, neuropathic agents), pelvic floor physical therapy, and psychotherapy forming the foundation. No controlled clinical trial of leech therapy for chronic prostatitis/CPPS has been published; use is investigational and mechanistic only, and the honest evidence grade is D. Interpretation is further limited by heterogeneous CPPS phenotypes, strong placebo effects, and confounding by concurrent multimodal therapy, and any perineal application would require extreme caution.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

Krashenyuk AI et al. (2010)0

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
NIH Category I/II prostatitis (bacterial — antibiotics first)
Active urinary tract infection
Recent prostate biopsy (<6 weeks)
Anticoagulation for cardiac indications
Perineal skin breakdown

Related Conditions

Peyronie's Disease (Stable Phase)

Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.

Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)

Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.

Interstitial Cystitis / Bladder Pain Syndrome (Investigational)

Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.

Peyronie's Disease (Extended Investigational Adjunct)

Highly investigational extended-protocol adjunct for stable Peyronie's disease; case reports only; collagenase clostridium histolyticum and surgical correction remain primary.